1-6 of 6
Juliane M. Jürgensmeier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer

Available to Purchase
Yohann Loriot, Arjun V. Balar, Daniel P. Petrylak, Arash R. Kalebasty, Petros Grivas, Aude Fléchon, Rohit K. Jain, Umang Swami, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, Mitch Sierecki, Marianna Zavodovskaya, Emon Elboudwarej, Lauri Diehl, Juliane M. Jürgensmeier, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3179–3188.
https://doi.org/10.1158/1078-0432.CCR-23-3924
Published: 01 August 2024
View articletitled, Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer
Open the PDF for Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Free
Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon A. Rule, Ebenezer A. Kio, Lionel Karlin, Martin J.S. Dyer, Siddhartha S. Mitra, Ping Cheng Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M. Jürgensmeier, Christopher D. Fegan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (12): 2810–2818.
https://doi.org/10.1158/1078-0432.CCR-19-3504
Published: 15 June 2020
View articletitled, Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Open the PDF for Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

Available to Purchase
Juliane M. Jürgensmeier, Joseph P. Eder, Roy S. Herbst
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4425–4435.
https://doi.org/10.1158/1078-0432.CCR-13-0753
Published: 01 September 2014
View articletitled, New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Open the PDF for New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs in another window
Journal Articles

Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma

Available to Purchase
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, Michael Leahy
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3603–3612.
https://doi.org/10.1158/1078-0432.CCR-13-1881
Published: 30 June 2014
View articletitled, Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Open the PDF for Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis

Available to Purchase
Osamu Takahashi, Ritsuko Komaki, Paul D. Smith, Juliane M. Jürgensmeier, Anderson Ryan, B. Nebiyou Bekele, Ignacio I. Wistuba, Jörg J. Jacoby, Maria V. Korshunova, Anna Biernacka, Baruch Erez, Keiko Hosho, Roy S. Herbst, Michael S. O'Reilly
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1641–1654.
https://doi.org/10.1158/1078-0432.CCR-11-2324
Published: 14 March 2012
View articletitled, Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Open the PDF for Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis in another window
Journal Articles

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

Available to Purchase
Neil R. Smith, Dawn Baker, Neil H. James, Kirsty Ratcliffe, Martin Jenkins, Susan E. Ashton, Graham Sproat, Ruth Swann, Neil Gray, Anderson Ryan, Juliane M. Jürgensmeier, Chris Womack
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3548–3561.
https://doi.org/10.1158/1078-0432.CCR-09-2797
Published: 14 July 2010
View articletitled, Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Open the PDF for Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers in another window
Includes: Supplementary data